Vitamin C treatment reduces elevated C-reactive protein

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Nutritional Science

Background:

• Plasma C-reactive protein (CRP) is a key inflammatory biomarker linked to cardiovascular disease (CVD) risk.
• Statins have demonstrated efficacy in reducing CVD incidence by lowering elevated CRP levels.
• The potential of antioxidants like vitamins C and E to modulate CRP requires investigation.

Purpose of the Study:

• To evaluate the efficacy of vitamin C and vitamin E supplementation in reducing CRP levels.
• To determine if baseline CRP concentration influences the effect of vitamin C or E on CRP.
• To explore the potential of vitamin C in managing obesity-related inflammatory conditions.

Main Methods:

• A randomized, placebo-controlled trial involving 396 healthy nonsmokers.
• Participants were assigned to receive 1000 mg/day vitamin C, 800 IU/day vitamin E, or placebo for 2 months.
• Statistical analysis examined treatment effects, including interactions with baseline CRP levels.

Main Results:

• No overall significant reduction in CRP was observed across all participants.
• A significant interaction revealed that vitamin C reduced CRP by 25.3% in participants with baseline CRP ≥ 1.0 mg/L (p=0.02).
• Vitamin E did not produce a significant effect on CRP levels. 75% of obese participants had CRP ≥ 1.0 mg/L.

Conclusions:

• Vitamin C supplementation effectively reduces CRP levels in individuals with elevated CRP (≥ 1.0 mg/L), similar to statin effects.
• Vitamin E supplementation did not demonstrate a significant impact on CRP levels.
• Future research should focus on individuals with elevated biomarkers to assess clinical benefits of antioxidants, particularly for obesity-related diseases.